Alfresa Holdings Corporation

Equities

2784

JP3126340003

Medical Equipment, Supplies & Distribution

Market Closed - Japan Exchange Other stock markets 07:00:00 17/07/2024 BST			5-day change	1st Jan Change
2,297 ^JPY	+1.23%		+6.17%	-4.15%

06-06	Healios Enters Alliance, Bond Purchase Deal with Alfresa	MT
05-28	Alfresa Holdings' Subsidiary Forms Pact with National Center for Child Health and Development to Supply Somatic Stem Cell Materials	MT

Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on November 4, 2021.

January 04, 2022 at 06:30 am

From November 4, 2021 to December 31, 2021, the company has repurchased 4,221,500 shares, representing 1.99% for ¥6,755.13 million. With this, the company has completed the repurchase of 4,221,500 shares, representing 1.99% for ¥6,755.13 million under the buyback announced on November 4, 2021.

Latest news about Alfresa Holdings Corporation

Healios Enters Alliance, Bond Purchase Deal with Alfresa	06-06	MT
Alfresa Holdings' Subsidiary Forms Pact with National Center for Child Health and Development to Supply Somatic Stem Cell Materials	05-28	MT
Alfresa's Fiscal 2023 Attributable Profit Rises 15% on Net Sales Growth	05-17	MT
Alfresa Holdings Corporation Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024	04-30	CI
Alfresa Holdings Corporation Revises Consolidated Earnings Guidance for the Full Year Ending March 31, 2024	04-30	CI
Alfresa Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	02-08	CI
Alfresa Holdings Corporation Provides Commemorative Dividend Guidance for the Fiscal Year Ending March 31, 2024	02-08	CI
Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024	02-08	CI
Alfresa Holdings Corporation Revises Consolidated Earnings Guidance for the First Half Ended September 30, 2023 and Fiscal Year March 31, 2024	31/10/23	CI
Alfresa Holdings Completes 35 Billion Yen Share Buyback program	04/10/23	MT
Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on May 15, 2023.	03/10/23	CI
Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on May 15, 2023.	02/10/23	CI
Alfresa Holdings Corporation's Equity Buyback announced on May 15, 2023, has closed with 15,201,200 shares, representing 7.65% for ¥34,999.80 million.	01/10/23	CI
Alfresa unit Cell Resources Partners with Miltenyi Biotec to Advance Cell Culture Automation in Gene Cell Therapy Market	22/08/23	MT
Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year Ending March 31, 2024	08/08/23	CI
Alfresa Holdings Corporation Provides Dividend Guidance for the Second Quarter and Year End of Fiscal Year Ending March 31, 2023	08/08/23	CI
Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on May 15, 2023.	03/07/23	CI
Alfresa Plans up to 35 Billion Yen Share Buyback; Shares Up 6%	16/05/23	MT
Alfresa Holdings Corporation Reports Earnings Results for the Full Year Ended March 31, 2023	15/05/23	CI
Alfresa Holdings Corporation Provides Commemorative Dividend Guidance for the Second Quarter 2024	15/05/23	CI
Alfresa Holdings Corporation Provides Dividend Guidance for the Second Quarter and Year End of Fiscal Year Ending March 31, 2023	15/05/23	CI
Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year Ending March 31, 2024	15/05/23	CI
Alfresa Holdings Corporation announces an Equity Buyback for 21,000,000 shares, representing 10.37% for ¥35,000 million.	15/05/23	CI
Alfresa Holdings Corporation Announces Notice Regarding Change for Representative Directors	15/05/23	CI
Alfresa Holdings Corporation authorizes a Buyback Plan.	14/05/23	CI

Chart Alfresa Holdings Corporation

Duration

Period

More charts

Company Profile

Alfresa Holdings Corporation is a Japan-based holding company primarily engaged in the wholesale of drugs. The Company operates in four business segments. The Pharmaceutical Wholesale segment is engaged in the wholesale of medical products, test reagents, as well as medical equipment and materials. The Self Medication Wholesale segment is engaged in the wholesale of general drugs. The Pharmaceutical Manufacture segment is engaged in the manufacture and sale of pharmaceuticals, test reagents, medical equipment and implements, as well as pharmaceutical powders. The Medical-Related segment is mainly engaged in operation of pharmacies. The others business is engaged in the information system business, the transportation business, the warehousing business, the insurance agency business, the real estate management business, the sale of miscellaneous goods, as well as the manpower dispatching business, among others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

04/08/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Alfresa Holdings Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2,297 JPY

Average target price

2,240 JPY

Spread / Average Target

-2.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ALFRESA HOLDINGS CORPORATION	-4.15%	2.67B
ABBOTT LABORATORIES	-4.90%	179B
MEDTRONIC PLC	-1.36%	100B
DEXCOM, INC.	-7.64%	46.16B
HOYA CORPORATION	+18.16%	44.81B
CENCORA, INC.	+9.63%	44.38B
METTLER-TOLEDO INTERNATIONAL, INC.	+13.63%	29.53B
TERUMO CORPORATION	+22.31%	25.83B
WEST PHARMACEUTICAL SERVICES, INC.	-7.12%	23.97B
STERIS PLC	+4.03%	22.5B

Other Medical Equipment, Supplies & Distribution